Email ID
Password
Sign me in automatically next time
Turbulence in some emerging markets doesn't worry GlaxoSmithKline: its senior vice president and area head, emerging markets/Australasia, Rogerio Ribeiro is ...
Having raised just over $90m in an IPO on NASDAQ last year, Nabriva Therapeutics will invest some $80m on two international Phase III trials of its lead ...
When the National Institute of Allergy and Infectious Diseases (NIAID) developed an experimental West Nile virus vaccine, it struggled to find an industry ...
Consolidation in the generics sector continued as Mylan NV picked up Sweden's Meda for $9.9bn, quickly answering analysts' questions about whether the company ...
In its sixth report the Jim O'Neill Review on Antimicrobial Resistance (AMR) is calling for wider use of vaccines and alternative approaches to tackle ...
 
Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop ...
Will biotechnology firms in 2016 keep up the momentum that resulted in a record-breaking $7.4bn in US venture capital raised by the industry last year? It's possible if early-stage funding keeps up ...
"The good news is that there is no news," said Sanofi's CEO Olivier Brandicourt, commenting on the company's diabetes franchise during its 2015 annual results presentation on Feb 9. "We delivered ...
Regeneron Pharmaceuticals Inc. turned in a strong quarter for its ophthalmology blockbuster Eylea (aflibercept), and predicts 20% growth for the drug's fifth year on the market. But the ...
 
Sandoz, Novartis AG's generic drugs unit, has confirmed it has filed a market authorization application in Europe for a biosimilar version of Amgen Inc.'s Neulasta (pegfilgrastim) – the company also ...
A Japanese Phase III trial investigating the first-line use of Chugai Pharmaceutical Co. Ltd's alectinib in lung cancer has been halted early following better than expected positive results, boding ...
A second positive Phase III clinical trial for AbbVie Inc. 's elagolix in the treatment of endometriosis pain in premenopausal women supports a new drug application (NDA) submission to the US FDA in ...
Things have gone from bad to worse for CTI BioPharma Corp. this week. Shares lost 60% of their value to close at $0.44 on Feb. 8 following news the US FDA had placed a partial clinical hold on ...
 
The Washington budget game every year goes the same way: The person in the White House sends a massive request of trillions of dollars up to Capitol Hill, where it's promptly declared dead on ...
Pharma firms in the EU have three years in which to ensure that all prescription products introduced into the supply chain carry the new safety feature comprising a "unique identifier" and a ...
Amgen Inc. looks to be in with a chance to push back its biggest rival, partners Sanofi and Regeneron Pharmaceuticals , and strive for dominance of the PCKS9 market space in the UK for patients with ...
The two biggest Washington drug lobbyist groups – the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organizatio n (BIO) –simultaneously launched ...
 
RECENT TWEETS    
11 February 2016






Regulatory, Legislative, Legal and Political Biopharma News

Also covered:

• It Was Shkreli's Show, But Pharma Was On Trial
• Amgen: Biosimilars 'Notice' Not Conditioned On 'Patent Dance'
• FDA 'Moon Shot' Center To Expedite Combo Cancer Drugs
• WHO Hopes 'Emergency' Declaration Speeds Zika Vaccine
• Plus other Washington news


Read more...

 
Neonatal Brain Injury: An R&D Landscape Needing Cultivation
05 February 2016
Laura Runkel and Gunilla Sturrock

Outlook of Big Pharma - Part 1 17 July 2015

Get the Flash Player to see this player.

Scrip 100
16 December 2015

EVENTS
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36